Quantcast

Latest Amyotrophic lateral sclerosis Stories

2014-08-08 08:25:57

GERMANTOWN, Md., Aug. 8, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months and six months ended June 30, 2014 and provided a business and clinical update. "We are pleased to report that 2014 has already seen the company achieve several major milestones. In late July, we completed the last of the surgeries in the NSI-566/ALS Phase II trial. Each of the patients in the final cohort have received a total of 16 million NSI-566 neural...

2014-08-07 23:12:05

Tom Looney, diagnosed with MSA in 2008, worked closely with tech industry icons, including Steve Jobs. His unique experiences and talents will now be utilized to represent patients and increase awareness for this rare and terminal neurological disorder. Wilmington, NC (PRWEB) August 07, 2014 The Multiple System Atrophy (MSA) Coalition, an organization dedicated to serving patients, caregivers and families touched by MSA, has announced the appointment of veteran tech industry exec Tom...

2014-08-04 08:57:44

MPG Max Planck researchers show that two products of the gene DJ-1 can increase the survival of neurons Parkinson’s disease affects neurons in the Substantia nigra brain region – their mitochondrial activity ceases and the cells die. Researchers at the Max Planck Institute of Molecular Cell Biology and Genetics show that supplying D-lactate or glycolate, two products of the gene DJ-1, can stop and even counteract this process: Adding the substances to cultured HeLa cells and to...

2014-08-04 08:29:33

GERMANTOWN, Md., Aug. 4, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The multicenter Phase II trial treated 15 ambulatory patients in five different dosing cohorts. The first 12 patients received injections in the cervical region of the spinal cord only, where the stem cells...

2014-08-01 23:07:34

In her new role, Sharon will focus on advocating for and supporting MSA families as well as on educating healthcare professionals unfamiliar with this rare neurological disorder. La Coste, TX (PRWEB) August 01, 2014 The Multiple System Atrophy Coalition, a growing nonprofit 501 (c) 3 organization dedicated to serving patients, caregivers and families affected by the neurological disorder Multiple System Atrophy (MSA), announced the appointment of Sharon Kramer Sutton of La Coste, TX to...

2014-07-31 23:17:56

In his new role, Dr. Kellerman will be representing the needs of current caregivers as well as focusing on educating healthcare professionals unfamiliar with this rare neurological disorder. New London, IA (PRWEB) July 31, 2014 The Multiple System Atrophy Coalition, a growing nonprofit 501(c) 3 organization dedicated to serving patients, caregivers and families affected by the neurological disorder Multiple System Atrophy (MSA), announced the appointment of Dr. Larry Kellerman of New...

2014-07-17 23:01:11

Annual Fill the Boot Campaigns Heat Up This Summer; Events Nationwide Benefit Children and Adults Fighting Muscle Disease. CHICAGO, (PRWEB) July 17, 2014 The Muscular Dystrophy Association and the International Association of Fire Fighters (IAFF) are set to kick off another summer season of the fire fighters' spirited Fill the Boot campaign. Throughout 2014, the two organizations are celebrating 60 years of a partnership committed to saving and improving the lives of more than one...

2014-07-16 23:03:05

ReportsnReports.com adds “OpportunityAnalyzer Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018” to its store. Patent Expiration of Rilutek to Cause Negative Growth in Amyotrophic Lateral Sclerosis Treatment Market by 2018. Dallas, TX (PRWEB) July 16, 2014 The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013 to $38 million by 2018, at a negative Compound Annual Growth Rate (CAGR) of 10.05%, according to...

2014-07-16 16:24:01

ABERDEEN, Scotland and SINGAPORE, July 16, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] announced it has achieved its target enrollment of 833 subjects into one of its two ongoing multi-center Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-16 08:29:14

--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population-- ALISO VIEJO, Calif., July 16, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA(®) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's disease/dementia. PBA is a distressing neurologic...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.